P.S. I think a 40 cent takeover offer would get over the line...

P.S. I think a 40 cent takeover offer would get over the line right now.


Many will argue with you @sarge17 but without a DEP® license deal and no global distribution for Viraleze this is a real possibility .... probably 50 - 60 cents would be more likely to get LT suffering shareholders to sell their shares and walk away from this mob now with all that has transpired.... many are sick of all the promises made to the market about DEP® 'commercial in confidence discussions' that have supposedly been going on for years with nothing coming to fruition ? (See some examples below)


In relation to our ADCs ... Merck have also opted to sink up to $22 billion for ADCs while paying $5.5 billion upfront to a competitor (Daiichi) after 'researching' Starpharma's ADCs for ~2 years and yet some still want to argue that our ADC research agreement with Merck is a big deal ? lol


IMHO either Starpharma are requesting too much money for the DEP® deals they have been in negotiations for OR big pharma just aren't interested in what JF & Co. are selling ? I welcome someone to offer another alternative as to why after all these years of 'commercial in confidence' negotiations we have seen diddly squat when it comes to DEP® license deals for any indication ?


.... and finally - pick a year folks .... go to most DEP® announcements and you will see we have been told exactly the same thing year after year after year after year after year with no DEP® license deal executed - quite astounding after all this time IMO




2023

Melbourne, Australia; 18 October 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) today announces the final positive results from its completed Phase 2 open-label clinical trial of DEP® cabazitaxel. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP® cabazitaxel in advanced, metastatic castrate-resistant prostate cancer (mCRPC), as well as other difficult-to-treat cancers, including platinum-resistant ovarian cancer and gastro-oesophageal cancers. The trial results also confirmed the favourable safety and tolerability profile of DEP® cabazitaxel.

Starpharma is engaged in ongoing commercial/licensing discussions with potential partners for DEP® cabazitaxel, and these final results form part of these discussions.





2021

Melbourne, Australia; 25 November 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced positive interim results from its ongoing phase 2 trial of DEP® cabazitaxel, showing that 100% (22/22) of evaluable3 patients with hormone refractory, (Stage IV) metastatic prostate cancer. All of these patients have been heavily pre-treated and have had efficacy responses, utilising one or more standard measures of disease.


Data from this cohort of prostate cancer patients is being presented in confidential commercial discussions with several potential pharmaceutical companies / partners.





2019

Melbourne, Australia; 28 August 2019: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that promising efficacy signals have been observed in its ongoing clinical trials for both DEP® cabazitaxel and DEP® docetaxel.

This exciting clinical data for both DEP® cabazitaxel and DEP® docetaxel continues to be fed into partnering discussions and has been positively received by potential partners.